Forte Biosciences Inc (FBRX) Stock Price, Quote & News

Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Industry: Biotechnology

Sector: Healthcare

Phone: 310 618 6994

Website: www.fortebiorx.com

Address:

3060 Pegasus Park Drive, Building 6, Dallas, United States

porky1963 May. 19 at 8:05 PM

$FBRX picked up a few more units at $20.19,its down 1/4 last few weeks but confident for the future.

0 · Reply

porky1963 May. 12 at 8:40 PM

$FBRX up + down again,letts see were we are end of june.

0 · Reply

porky1963 May. 4 at 12:38 PM

$FBRX still holding,will not go anywere untill $40.00.HOPEFULLY next year.

0 · Reply

Quantumup Apr. 28 at 11:36 AM

H.C. Wainwright🏁 $TRAX.X Buy; $30., and said: A biopharma spin-out equipped with a pipeline of high potency immunomodulators. $ANAB $FBRX NVS EPRX BMY ABBV REGN AMGN BIIB ARGX KNSA Here's what else H.C. Wainwright had to say in its initiation report: https://x.com/Quantumup1/status/2049089378358645033?s=20

0 · Reply

Quantumup Apr. 22 at 10:37 AM

Barclays🏁 $TRAX.X and said: We initiate coverage of First Tracks Biotherapeutics at Overweight with a $40 PT, in the wake of the spin from AnaptysBio (ANAB, OW). $ANAB $NVS $FBRX $TEVA RPRX EPRX Here's what else Barclays had to say in its First Tracks Biotherapeutics initiation report:

0 · Reply

Doozio Apr. 20 at 10:20 PM

$CRNC $FBRX about ONTO 🐒🍌🧠⏰♾️

0 · Reply

Doozio Apr. 19 at 4:29 PM

All the way up da Roger n $FBRX et about it?

0 · Reply

porky1963 Apr. 11 at 4:53 PM

$FBRX well you can't say this is a boreing share to hold.still holding for long run,will probablly have news june on how it's performing.it's leaps and bounds last week so of the next few weeks will be of great intrest.will not purchase anymore gone far to expensive for me.they have a very clever team and given time they will suprise us if a few things go well.

0 · Reply

fallondpicks Apr. 9 at 10:59 PM

18 #stockbreakouts $CLSE, $FBRX, $GUYGF (gap), $STAA (gap and 200-day MA), $VOLT. Two sub-$1, three $1-2.

0 · Reply

ClassifiedTrades Apr. 9 at 8:25 PM

$BBGI $FBRX $ELAB

0 · Reply

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

2026-05-11T14:15:25.000Z - 9 days ago

Forte Biosciences reports Q1 EPS ($1.24), consensus ($1.16)

May 11, 2026, 9:01 AM EDT - 9 days ago

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

May 11, 2026, 7:00 AM EDT - 9 days ago

Forte Biosciences Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 9 days ago

Forte Biosciences Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 21 days ago

Forte Biosciences Proxy statement: Proxy filing

2026-04-09T01:35:11.000Z - 5 weeks ago

Forte Biosciences 5.71M share Spot Secondary priced at $26.27

Apr 8, 2026, 9:30 PM EDT - 5 weeks ago

Forte Biosciences Announces Pricing of $150 Million Public Offering

2026-04-08T20:16:12.000Z - 6 weeks ago

Forte Biosciences announces common stock offering, no amount given

Apr 8, 2026, 4:02 PM EDT - 6 weeks ago

Forte Biosciences Announces Proposed Public Offering

2026-03-31T20:07:05.000Z - 7 weeks ago

Forte Biosciences reports FY25 EPS ($4.71) vs. ($12.17) last year

Mar 31, 2026, 4:01 PM EDT - 7 weeks ago

Forte Biosciences, Inc. Announces 2025 Results and Provides Update

Mar 31, 2026, 7:00 AM EDT - 7 weeks ago

Forte Biosciences Earnings release: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 7 weeks ago

Forte Biosciences Annual report: Q4 2025

Mar 17, 2026, 4:01 PM EDT - 2 months ago

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Mar 4, 2026, 4:01 PM EST - 2 months ago

Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules

Feb 9, 2026, 4:01 PM EST - 3 months ago

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

2025-11-25T11:35:12.000Z - 6 months ago

Forte Biosciences initiated with an Outperform at Evercore ISI

2025-11-14T14:05:46.000Z - 6 months ago

Forte Biosciences reports Q3 EPS (99c), consensus ($1.07)

Nov 14, 2025, 9:00 AM EST - 6 months ago

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Nov 14, 2025, 7:00 AM EST - 6 months ago

Forte Biosciences Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 6 months ago

Forte Biosciences Quarterly report: Q3 2025

Nov 3, 2025, 4:01 PM EST - 7 months ago

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Sep 15, 2025, 9:00 AM EDT - 8 months ago

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

2025-08-18T10:45:47.000Z - 9 months ago

Forte Biosciences initiated with a Buy at Guggenheim on FB102 potential

2025-08-18T10:15:54.000Z - 9 months ago

Forte Biosciences initiated with a Buy at Guggenheim

2025-08-14T20:06:04.000Z - 9 months ago

Forte Biosciences reports Q2 EPS (96c), consensus ($1.11)

Aug 14, 2025, 4:01 PM EDT - 9 months ago

Forte Biosciences, Inc. Announces Results and Provides Update

Aug 14, 2025, 4:00 PM EDT - 9 months ago

Forte Biosciences Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 9 months ago

Forte Biosciences Quarterly report: Q2 2025

Jun 25, 2025, 12:28 AM EDT - 11 months ago

Forte Biosciences Announces Pricing of $75 Million Public Offering

2025-06-24T20:05:55.000Z - 11 months ago

Forte Biosciences announces common stock offering, no amount given

2025-06-23T23:53:00.000Z - 11 months ago

Forte Biosciences Stock (FBRX) Surges 25% on Positive Celiac Disease Trial Data

2025-06-23T17:06:06.000Z - 11 months ago

Forte Biosciences announces data from trial in celiac disease for FB102

Jun 23, 2025, 8:30 AM EDT - 11 months ago

Forte Biosciences Transcript: Study Update

Jun 23, 2025, 8:30 AM EDT - 11 months ago

Forte Biosciences Press release: Study Update

Jun 23, 2025, 8:30 AM EDT - 11 months ago

Forte Biosciences Slides: Study Update

Jun 23, 2025, 7:18 AM EDT - 11 months ago

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

2025-06-05T10:10:23.000Z - 1 year ago

Forte Biosciences initiated with a Buy at Lucid Capital

2025-05-15T20:05:13.000Z - 1 year ago

Forte Biosciences reports Q1 EPS ($1.37), consensus (95c)

May 15, 2025, 4:00 PM EDT - 1 year ago

Forte Biosciences Earnings release: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

Forte Biosciences Quarterly report: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Forte Biosciences Proxy statement: Proxy Filing

2025-04-01T22:10:14.000Z - 1 year ago

Forte Biosciences price target lowered to $61 from $64 at Chardan

Mar 31, 2025, 9:00 AM EDT - 1 year ago

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Mar 30, 2025, 6:00 PM EDT - 1 year ago

Forte Biosciences Earnings release: Q4 2024

Mar 30, 2025, 6:00 PM EDT - 1 year ago

Forte Biosciences Annual report: Q4 2024

2025-03-28T20:50:48.000Z - 1 year ago

Forte Biosciences files $300M mixed securities shelf

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Forte Biosciences Registration statement: Registration Filing

2025-01-21T10:45:13.000Z - 1 year ago

Forte Biosciences initiated with a Buy at TD Cowen

Dec 31, 2024, 7:00 AM EST - 1 year ago

Forte Biosciences Proxy statement: Proxy Filing

Dec 13, 2024, 7:00 AM EST - 1 year ago

Forte Biosciences Registration statement: Registration Filing

Nov 25, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences to Host R&D Day December 3, 2024

Nov 20, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Nov 14, 2024, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Nov 14, 2024, 4:00 PM EST - 1 year ago

Forte Biosciences Quarterly report: Q3 2024

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Aug 14, 2024, 12:01 PM EDT - 1 year ago

Forte Biosciences Quarterly report: Q2 2024

Aug 14, 2024, 12:01 PM EDT - 1 year ago

Forte Biosciences Earnings release: Q2 2024

Jul 30, 2024, 8:00 AM EDT - 1 year ago

Forte Biosciences Proxy statement: Proxy Filing

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Forte Biosciences Proxy statement: Proxy Filing

May 13, 2024, 4:05 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

May 13, 2024, 7:00 AM EDT - 2 years ago

Forte Biosciences Quarterly report: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Forte Biosciences Earnings release: Q1 2024

Mar 18, 2024, 4:05 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Forte Biosciences Earnings release: Q4 2023

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Forte Biosciences Annual report: Q4 2023

Nov 13, 2023, 4:01 PM EST - 2 years ago

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

Nov 13, 2023, 4:00 PM EST - 2 years ago

Forte Biosciences Quarterly report: Q3 2023

Sep 14, 2023, 10:50 AM EDT - 2 years ago

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Sep 6, 2023, 3:15 PM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Sep 1, 2023, 8:00 AM EDT - 2 years ago

Forte Biosciences Proxy statement: Proxy Filing

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Forte Biosciences Proxy statement: Proxy Filing

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Forte Biosciences Registration statement: Registration Filing

Aug 25, 2023, 8:00 AM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Aug 24, 2023, 8:00 AM EDT - 2 years ago

Forte Biosciences Proxy statement: Proxy Filing

Aug 24, 2023, 8:00 AM EDT - 2 years ago

Forte Biosciences Proxy statement: Proxy Filing

Aug 14, 2023, 4:01 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Forte Biosciences Quarterly report: Q2 2023

Aug 2, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Proxy statement: Proxy Filing

Aug 1, 2023, 4:01 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

May 25, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Proxy statement: Proxy Filing

May 15, 2023, 4:01 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

Mar 31, 2023, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Mar 31, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Annual report: Q4 2022

Jan 12, 2023, 4:05 PM EST - 3 years ago

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Aug 17, 2022, 8:00 AM EDT - 4 years ago

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Aug 15, 2022, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Jun 7, 2022, 9:00 AM EDT - 4 years ago

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

May 19, 2022, 8:00 AM EDT - 4 years ago

Forte Biosciences Proxy statement: Proxy Filing

May 16, 2022, 9:00 AM EDT - 4 years ago

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

Apr 29, 2022, 8:00 AM EDT - 4 years ago

Forte Biosciences Proxy statement: Proxy Filing

Mar 31, 2022, 8:00 AM EDT - 4 years ago

Forte Biosciences Annual report: Q4 2021

Sep 3, 2021, 12:19 PM EDT - 5 years ago

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Sep 3, 2021, 7:21 AM EDT - 5 years ago

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Sep 2, 2021, 4:05 PM EDT - 5 years ago

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Aug 16, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

May 28, 2021, 8:00 AM EDT - 5 years ago

Forte Biosciences Registration statement: Registration Filing

May 10, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

May 3, 2021, 4:30 PM EDT - 5 years ago

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

Apr 30, 2021, 8:00 AM EDT - 5 years ago

Forte Biosciences Proxy statement: Proxy Filing

Mar 24, 2021, 8:00 AM EDT - 5 years ago

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Mar 17, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Mar 16, 2021, 8:00 AM EDT - 5 years ago

Forte Biosciences Annual report: Q4 2020

Feb 23, 2021, 4:01 PM EST - 5 years ago

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

Feb 18, 2021, 4:01 PM EST - 5 years ago

Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st

Nov 24, 2020, 4:05 PM EST - 5 years ago

Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd

porky1963 May. 19 at 8:05 PM

$FBRX picked up a few more units at $20.19,its down 1/4 last few weeks but confident for the future.

0 · Reply

porky1963 May. 12 at 8:40 PM

$FBRX up + down again,letts see were we are end of june.

0 · Reply

porky1963 May. 4 at 12:38 PM

$FBRX still holding,will not go anywere untill $40.00.HOPEFULLY next year.

0 · Reply

Quantumup Apr. 28 at 11:36 AM

0 · Reply

Quantumup Apr. 22 at 10:37 AM

0 · Reply

Doozio Apr. 20 at 10:20 PM

$CRNC $FBRX about ONTO 🐒🍌🧠⏰♾️

0 · Reply

Doozio Apr. 19 at 4:29 PM

All the way up da Roger n $FBRX et about it?

0 · Reply

porky1963 Apr. 11 at 4:53 PM

0 · Reply

fallondpicks Apr. 9 at 10:59 PM

18 #stockbreakouts $CLSE, $FBRX, $GUYGF (gap), $STAA (gap and 200-day MA), $VOLT. Two sub-$1, three $1-2.

0 · Reply

ClassifiedTrades Apr. 9 at 8:25 PM

$BBGI $FBRX $ELAB

0 · Reply

focafoca99 Apr. 9 at 7:50 PM

$FBRX priced a $150 million public offering at $26.27 per share.

0 · Reply

LewisDaKat Apr. 9 at 4:00 PM

$FBRX Forte Biosciences Inc. (NASDAQ: FBRX) Rises Sharply in 4/9 Early Trading Session https://marketwirenews.com/stock/fbrx/news/forte-biosciences-inc-nasdaq-fbrx-rises-sharply-in-4-7062459549742409.html?utm_source=stocktwits

0 · Reply